文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

西达本胺联合R-CHOP对比R-CHOP一线治疗MYC/BCL2双表达弥漫大B细胞淋巴瘤的随机临床试验

Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

这项在中国40个中心开展的随机双盲安慰剂对照3期试验纳入423例初治MYC/BCL2双表达弥漫大B细胞淋巴瘤患者,评估西达本胺联合R-CHOP对比单用R-CHOP的疗效与安全性。

要点

  • 西达本胺联合R-CHOP较单用R-CHOP显著改善初治DEL患者的无事件生存。
  • 联合组2年无事件生存率60.3%,对照组50.5%,分层HR 0.72。
  • 联合组完全缓解率73.0%,较对照组61.8%提高11.1个百分点。

核心结论

  • 西达本胺联合R-CHOP显著改善初治MYC/BCL2双表达弥漫大B细胞淋巴瘤患者的无事件生存,毒性可控。
  • 该试验首次证明表观遗传调节剂在弥漫大B细胞淋巴瘤中的获益,为高危人群提供同时靶向MYC与BCL2的一线新策略。

研究设计与样本

  • 随机、双盲、安慰剂对照3期试验,2020年5月21日至2022年7月25日入组,随访至2025年6月26日。
  • 中国40个研究中心,共纳入423例符合条件患者,按1:1随机分配。
  • 方案为口服西达本胺(每21天周期第1、4、8、11天20 mg)或匹配安慰剂联合6周期R-CHOP;联合治疗后达完全缓解者接受西达本胺或安慰剂维持治疗至24周。
  • 主要终点为无事件生存,次要终点包括完全缓解率、无进展生存、无病生存、总生存和耐受性。

主要发现

  • 423例随机患者中位年龄63岁,男性占47.5%,自随机化起中位随访41.3个月。
  • 2年无事件生存率西达本胺组60.3%,安慰剂组50.5%。
  • 完全缓解率西达本胺组73.0%,安慰剂组61.8%,差异11.1%(95%CI 2.3%-20.0%)。
  • 西达本胺组治疗相关毒性增加,但总体可通过支持治疗管理。

关键数值与推荐

  • 2年无事件生存率:西达本胺组60.3%,安慰剂组50.5%。
  • 完全缓解率:西达本胺组73.0%,安慰剂组61.8%,差异11.1%(95%CI 2.3%-20.0%)。

临床怎么用

  • 对初治MYC/BCL2双表达弥漫大B细胞淋巴瘤患者,可考虑西达本胺联合R-CHOP作为一线治疗选择。
  • 联合治疗期间需关注毒性增加,并给予相应支持治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Epigenetic dysregulation is associated with the pathogenesis and progression of diffuse large B-cell lymphoma (DLBCL). MYC/BCL2 double-expressor lymphoma (DEL), a distinct population of DLBCL defined by MYC and BCL2 coexpression, refers to poor prognosis after standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) immunochemotherapy. Tucidinostat (or chidamide), an oral, selective histone deacetylase inhibitor, has shown promising activity in DEL. OBJECTIVE: To evaluate efficacy and safety of tucidinostat plus R-CHOP vs R-CHOP alone as first-line treatment for patients with DEL. DESIGN, SETTING, AND PARTICIPANTS: This randomized, double-blind, placebo-controlled phase 3 trial enrolled patients from May 21, 2020, through July 25, 2022, with follow-up to June 26, 2025. The trial was conducted at 40 study centers in China; a total of 423 eligible patients were enrolled. INTERVENTIONS: Patients were randomly assigned in a 1:1 ratio to receive oral tucidinostat (20 mg on days 1, 4, 8, and 11 of each 21-day cycle) or matching placebo, plus 6 cycles of R-CHOP. Patients with a complete response after combination therapy received either tucidinostat or placebo maintenance up to 24 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was event-free survival. Secondary end points included complete response rate, progression-free survival, disease-free survival, overall survival, and tolerability. RESULTS: Among 423 patients randomized (median age, 63 years; 47.5% male), the median follow-up duration from randomization was 41.3 months. The tucidinostat group demonstrated a 28% lower risk of disease progression, relapse after complete response, death, or initiation of new therapy for residual disease compared with the placebo group (stratified hazard ratio, 0.72 [95% CI, 0.54-0.96]; P = .02), with a 2-year event-free survival rate of 60.3% vs 50.5%, respectively. The complete response rate was 73.0% vs 61.8% (difference, 11.1% [95% CI, 2.3%-20.0%]), respectively. Increased toxicity associated with treatment was observed in the tucidinostat group but generally manageable with supportive care. CONCLUSIONS AND RELEVANCE: Tucidinostat plus R-CHOP significantly improved event-free survival, with manageable toxicity in patients newly diagnosed with DEL. This trial is the first to demonstrate the benefit of an epigenetic modulator in DLBCL, offering a new first-line therapeutic approach dually targeting MYC and BCL2 oncoprotein for this high-risk population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04231448.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Xu PP, Song YQ, Shen JZ, et al. Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial. JAMA. 2026. PMID: 42018318. doi:10.1001/jama.2026.4199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。